Companies › Acrotech Biopharma
2 active drug programs in 13 registered trials: 8 Phase 1, 3 Phase 2, 2 Phase 3; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pralatrexate Dihydrofolate reductase inhibitor | DHFR | Phase 3 | Peripheral T Cell Lymphoma; Advanced Solid Tumors; Lymphoma, T-Cell; PTCL … | Feb 2027 |
| Belinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 3 | Peripheral T Cell Lymphoma; Locally Advanced Unresectable Primary Central Chondrosarcoma; Carcinoma, Neuroendocrine; Metastatic Uveal Melanoma … | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03161223 | Pralatrexate | Phase 1 | Lymphoma, T-Cell | Oncology | Feb 2023 |
| NCT03240211 | Pralatrexate | Phase 1 | PTCL | Oncology | Jul 2025 |
| NCT04340843 | Belinostat | Phase 2 | Locally Advanced Unresectable Primary Central Chondrosarcoma | Oncology | Jan 2027 |
| NCT07036133 | Pralatrexate | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
| NCT03598998 | Pralatrexate | Phase 1 | Anaplastic Large Cell Lymphoma | Oncology | Feb 2027 |
| NCT05627245 | Belinostat | Phase 1 | Recurrent B-Cell Non-Hodgkin Lymphoma | Oncology | Jun 2027 |
| NCT06406465 | Belinostat | Phase 2 | Carcinoma, Neuroendocrine | Oncology | Jul 2027 |
| NCT05170334 | Belinostat | Phase 2 | Metastatic Uveal Melanoma | Oncology | Jan 2028 |
| NCT07691450 | Belinostat | Phase 1 | Recurrent Anaplastic Large Cell Lymphoma | Oncology | Nov 2029 |
| NCT07691450 | Pralatrexate | Phase 1 | Recurrent Anaplastic Large Cell Lymphoma | Oncology | Nov 2029 |
| NCT06072131 | Belinostat | Phase 3 | Peripheral T Cell Lymphoma | Oncology | Jul 2030 |
| NCT06072131 | Pralatrexate | Phase 3 | Peripheral T Cell Lymphoma | Oncology | Jul 2030 |
| NCT07225985 | Pralatrexate | Phase 1 | Recurrent T-Cell Non-Hodgkin Lymphoma | Oncology | Sep 2030 |
Great Novel Therapeutics Biotech & Medicals Xynomic Pharmaceuticals Italfarmaco LaNova Medicines Zhejiang Quetzal Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.